PSOCAPS

Food supplement based on fumaric acid salts, useful for the treatment of medium / mild forms of psoriasis vulgaris.

Ingrediants
Active ingredients: salified fumaric acid (120 mg of fumarate per 1 capsule).
Other components: cellulose; calcium carbonate; magnesium chelate; potassium carbonate; anti-caking agent (silicon dioxide; magnesium stearate; zinc oxide; vitamin B6; glazing agent (shellac, castor oil).

How to use
A gradual dosage is recommended, in order to obtain an optimal set of efficacy and tolerability. The maximum dose of 3 times 2 gastro-resistant tablets of the product must NOT be exceeded. In many cases, however, the administration of the maximum daily dose is not necessary. First therapeutic effects are usually noticeable after the fourth week of treatment.
After improvement of skin reactions, attempts are made to slowly reduce the daily intake until the required maintenance dose is reached on a case-by-case basis.
The gastro-resistant capsules should be swallowed without chewing with a good amount of liquid during or immediately after meals. In general, a sufficient amount of fluids (1-2 liters) should be consumed during the day.
The duration of treatment is determined by the attending physician. There is sufficient experience with treatment lasting 4 months. Although there are data for treatments lasting up to 36 months, it is advisable not to extend treatment beyond 6 months.

Contraindications
The product must not be used in case of severe gastrointestinal diseases such as gastric ulcer and duodenal ulcer, and in case of severe liver and kidney diseases; do not administer to patients under 12 years of age.
Although based on experimental data in laboratory animals there are no indications of a teratogenic action, the product should not be used during pregnancy and lactation, as there is no experience with pregnant patients and it is not known whether the substances pass into the milk. maternal.

Warnings
Do not exceed the recommended daily dose.
Keep out of the reach of children under three years of age.
Supplements are not intended as a substitute for a varied diet.

Side effects
Facial redness and flushing are frequent at the beginning of treatment, and very rarely gastralgia and diarrhea. In the course of treatment these disorders generally subside. If they are very pronounced, however, they can lead to an interruption of treatment.
Other disorders affecting the digestive system such as stomach heaviness, epigastric pains and meteorism are also rare.
Nausea, somnolence, lightheadedness and headache are rarely reported. These side effects usually disappear during treatment. In most cases, a dose reduction is sufficient to relieve the symptoms. However, if these side effects are not reduced, it is up to the treating physician to decide on the continuation of therapy. During therapy with PSOCAPS as with any product containing fumes acid derivatives, metric blood count changes such as leukopenia, lymphopenia and mild eosinophilia are often observed.

Precautions
Before starting and at the end of a course of treatment with the product, a complete blood count (with leukocyte formula and platelet count) is recommended. If, on medical advice, the recommended dosage is exceeded, periodic blood counts and blood counts must be checked during treatment.
Likewise, the activity of SGOT, SGPT, gamma-GT, and the concentration of plasma creatinine, proteins and sediment in the urine must be analyzed before the beginning and at the end of the treatment, in order to check possible hypersensitivity effects.

Interactions with other preparations
Methotrexate, retinoids, psoralen, cyclosporins, immunosuppressants, cytostatics and medicines known to have a negative effect on kidney function should not be administered concurrently with the product.

storage
Keep away from light sources and in places inaccessible to children. Keep in a cool and dry place. The expiry date refers to the product in an integral package that has been correctly stored.

Format
60 gastro-resistant capsules.

Bibliography
- Grimble GK 'The significance of peptides in clinicalnutrition' Annu. Rev. Nutr. 1994; 14: 419-47
- Young VE & El-Khoury AE 'The notion of the nutritionalessentiality of amino acids, revisited, with a note on the indispensable amino acidrequirements in adults'. Amino Acid Metabolism and Therapy in Health and Nutritional Diseases (Cynober, L., ed.) 1995; 191-232
- Fürst P. 'Old and New Substrates in ClinicalNutrition' Amer. Soc. For Nutritional Sciences J. Nutr. 1998; 128: 789-796
- Wahba A, Cohen H, Bar-Eli M, Gallily R 'Neutrophilchemotaxis in psoriasis' Acta Derm. Venereol. (Stockh) 1979; 59: 441-445
- Geerdink JPM, Bergers M, Van Erp PEJ, Gommans JM, Mier PD, Roelfzema H. 'Cyclic AMP is decreased in mononuclear leukocytes from psoriasispatients' Br. J. Dermatol. 1980; 103: 107-108
- Harpaz S, Fink A, Zuckermann F, Muhammed E. 'Lymphocytecyclic nucleotide and prostaglandin content in psoriasis: a preliminary report'Arch. Dermatol. 1980; 116: 427-428
- Marcello CL, Duell EA 'Cyclic AMP stimulates and inhibitsadult human epidermal cell growth' J. Invest. Dermatol. 1979; 72: 279
- Goldberg ND, Haddox MK 'Cyclic GMP metabolism andinvolvement in biological regulation'. In: Snell EE, Boxne PD, Meister A, Richardson CC, eds. Annual Review of Biochemistry. Palo Alto, CA: Palo Alto Annual Review 1977; 823-896
- Kiehl R. and Ionescu G. 'A Defective Purine NucleotideSynthesis Pathway in psoriatic Patients' Acta Derm. Venereol. (Stockh) 1992; 72: 253-255
- Lajtha LG, Vane JR 'Dependence of bone marrow cells on the liver for purine supply' Nature 1958; 182: 191-192
- Henderson JF, Le Page GA 'Transport of adenosine-8-C14 among tissues by blood cells' J. Biol. Chem. 1959; 234: 3219-3223
- McManus TJ 'Alternate pathway for metabolism: acomparative view'. In: Greenwalt TJ, Janneson GA, eds. 'The human cell I invite'. New York: Grune and Stratton 1974; 49-63
- Kim HD, Zeidler RB, Sallis J, Nicol S, Isaacks RE'Metabolic properties of low ATP erythrocytes of the monotremes' FEBS Lett. 1984; 167: 83-87
- Kim HD 'Is adenosine a second metabolic substrate forhuman red blood cells?' Biochim. Biophys. Acta 1990; 1036: 113-120
- Lüthje J. 'Extracellular adenine compounds, redblood cells and haemostasis: facts and hypotheses' Blut 1985; 59: 367-374 -. Ledwon LM 'PSOCAPSriasis: new therapeutic indications associated with homotoxicology' Italian Journal of Homotoxicology 1993; 4: 19-29
- Yamamoto AI, Senshu T, Takahashi H, Akiyama K, Nomura K, IizukaH 'Decreased Deiminated Keratin K1 in PSOCAPSriatic HyperproliferativeEpidermis' Journal of Investigative Dermatology 2000; 114: 701-705
- Van Dijk E 'Fumarsäuretherapie - Stand der Forschungund offene Fragen' Wissenschaftlisches Beiheft 6 1990
- Verger Ph, Chambolle M, Babayou P, Le Breton S., Volatier JL'Estimation of the distribution of the maximum theoretical intake for ten additivesin France 'Food Additives and Contaminants 1998; Vol. 15; 7: 759-766